Oxis appoints new SAB member
This article was originally published in Scrip
Executive Summary
Oxis International, a biotechnology company focused on cannabinoid therapy development and commercialization, has named Dr Lisa A Haile a member of the scientific advisory board for its wholly owned subsidiary, Oxis Biotech. Dr Haile currently serves as co-chair, global life sciences sector at DLA Piper, where she is also a member of the firm's executive committee. She has specific technical expertise in molecular biology and immunology.